Kali-Extracts, Inc. again confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY's proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's U.S. Patented Cannabis Extraction Process. As detailed in a recently published research study (Journal of Cannabis Research) the KALY U.S. Patented CBD extract provides significant anti-inflammatory responses in vitro. The next phase of research is now moving forward in preclinical in vivo research to expand evaluation of the effects on lung function, total body distribution, whole body clearance of the extract and dosage evaluations for maximal efficacy. KALY has filed a new patent application specifically on its CBD formulation for symptoms associated with COPD and other similar respiratory conditions. KALY has also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions that result from respiratory inflammation.